Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Talisman Metals PLC

Capitalization 1.11M 1.27M 999K 954K 1.74M 118M 1.8M 11.89M 4.72M 56.2M 4.78M 4.68M 203M P/E ratio 2023
-0.18x
P/E ratio 2024 -2.12x
Enterprise value -1.4M -1.61M -1.27M -1.21M -2.2M -149M -2.28M -15.07M -5.99M -71.24M -6.06M -5.93M -257M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
55.33%
Yield 2023 *
-
Yield 2024 -
1 day-5.56%
1 week-10.53%
Current month-17.07%
1 month-34.62%
3 months+146.38%
6 months+146.38%
Current year+146.38%
1 week 8
Extreme 8
10
1 month 8
Extreme 8
13
Current year 5
Extreme 5
14
1 year 3.14
Extreme 3.135
14
3 years 1.35
Extreme 1.353
44.4
5 years 1.35
Extreme 1.353
78
10 years 1.35
Extreme 1.353
89.82
Change 5d. change 1-year change 3-years change Capi.($)
-5.56%-10.53%+102.38%-52.78% 7.46M
-2.62%-1.60%+13.91%+90.54% 44.8B
-1.06%-0.58%+49.23%+14.57% 40.35B
+0.09%-2.82%+88.44%+675.97% 30.05B
-0.81%-11.62%-10.18%-29.31% 21.8B
-1.08%-4.40%+49.10%-30.80% 19.09B
-0.91%-1.94%+26.81%-29.36% 16.72B
0.00%+3.54%+56.92%+180.20% 13.53B
-3.86%+3.48%-22.35%+937.58% 12.47B
+1.65%+2.12%+65.71% - 12.1B
Average -1.42%+1.29%+42.00%+195.18% 21.09B
Weighted average by Cap. -1.13%+0.30%+36.59%+187.94%

Financials

2023 2024
Net sales - -
Net income -4.7M -5.42M -4.25M -4.06M -7.38M -500M -7.64M -50.6M -20.09M -239M -20.34M -19.91M -863M -746K -860K -675K -644K -1.17M -79.4M -1.21M -8.03M -3.19M -37.94M -3.23M -3.16M -137M
Net Debt -3.34M -3.85M -3.02M -2.88M -5.24M -355M -5.42M -35.91M -14.26M -170M -14.44M -14.13M -613M -2.51M -2.89M -2.27M -2.16M -3.94M -267M -4.07M -26.97M -10.71M -127M -10.84M -10.61M -460M
Logo Talisman Metals PLC
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal spray. The spray delivers the drug to olfactory and trigeminal nerves in the nasal cavity where the drug accumulates in the olfactory bulb and further in the brain. It is also developing a new treatment for women affected by low libido or sex drive. It owns a patent portfolio that provides effective protection of its technology. The Company operates in Ireland, the United Kingdom and Russia.
Employees
1
Date Price Change Volume
26-03-12 8.500 p -5.56% 3,862
26-03-11 9.000 p -5.26% 60,123
26-03-10 9.500 p 0.00% 16,696
26-03-09 9.500 p 0.00% 309
26-03-06 9.500 p 0.00% 14,999
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW